Li Mou Zheng

Net worth: 265 M $ as of 31/03/2024

71 year

Health Technology

Health Services

Profile

Li Mou Zheng is the founder of Amoy Diagnostics Co., Ltd., which was founded in 2008.
He currently holds the position of Chairman at Amoy Diagnostics Co., Ltd.
Additionally, Dr. Zheng is currently the Chairman at SinoPath Medical Investment (Beijing) Co., Ltd.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
AMOY DIAGNOSTICS CO., LTD. CLASS A 22.06%	30/09/2023	87,701,616 ( 22.06% )	265 M $	31/03/2024

Li Mou Zheng active positions

Companies	Position	Start
AMOY DIAGNOSTICS CO., LTD.	Founder	21/02/2008
SinoPath Medical Investment (Beijing) Co., Ltd. SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China.	Chairman	-

All active positions of Li Mou Zheng

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Li Mou Zheng's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
AMOY DIAGNOSTICS CO., LTD.	Health Technology

Private companies	1
SinoPath Medical Investment (Beijing) Co., Ltd. SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China.	Health Services